Bridget A.  Ross net worth and biography

Bridget Ross Biography and Net Worth

Director of LeMaitre Vascular

Bridget A. Ross has served as a member of the Board of Directors since April 2020.  Since February 2020, Ms. Ross has served as CEO of ChroniSense Medical, Ltd., developer of a wearable medical-grade disease management device, and since January 2020, she has also served as advisor to Picomole, Inc., a medical technology company focused on developing a breath test for lung cancer.  Additionally, Ms. Ross serves on the steering committee of MassMedic and as the Executive in Residence for the association's IGNITE accelerator program.  From 2017 to 2018, Ms. Ross was President of the Global Medical Group and member of the Executive Management team at Henry Schein, Inc., an international medical and dental product distributor/solutions provider.  From 1988 to 2017 she held numerous senior leadership roles at Johnson & Johnson, Inc., including, most recently VP of Commercial Operations for Medical Devices, North America.  Ms. Ross holds a Bachelor of Commerce degree from the University of Alberta.  The Board has concluded that Ms. Ross should serve on our Board due to her strong executive management skills, knowledge of the medical device industry and breadth of functional, geographic, and therapeutic experience gained during her 30+ year career.

What is Bridget A. Ross' net worth?

The estimated net worth of Bridget A. Ross is at least $209,029.28 as of November 15th, 2024. Ross owns 2,278 shares of LeMaitre Vascular stock worth more than $209,029 as of April 24th. This net worth estimate does not reflect any other assets that Ross may own. Learn More about Bridget A. Ross' net worth.

How do I contact Bridget A. Ross?

The corporate mailing address for Ross and other LeMaitre Vascular executives is 63 SECOND AVENUE, BURLINGTON MA, 01803. LeMaitre Vascular can also be reached via phone at (781) 221-2266. Learn More on Bridget A. Ross' contact information.

Has Bridget A. Ross been buying or selling shares of LeMaitre Vascular?

Bridget A. Ross has not been actively trading shares of LeMaitre Vascular over the course of the past ninety days. Most recently, Bridget A. Ross sold 3,750 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a transaction totalling $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company's stock, valued at $231,148.66. Learn More on Bridget A. Ross' trading history.

Who are LeMaitre Vascular's active insiders?

LeMaitre Vascular's insider roster includes Lawrence Jasinski (Director), Trent Kamke (Senior Vice President, Operations), George Lemaitre (Chairman & CEO), Joseph Pellegrino, Jr. (CFO), David Roberts (Director), Bridget Ross (Director), and John Roush (Director). Learn More on LeMaitre Vascular's active insiders.

Are insiders buying or selling shares of LeMaitre Vascular?

In the last twelve months, insiders at the medical instruments supplier sold shares 10 times. They sold a total of 136,441 shares worth more than $10,888,005.35. The most recent insider tranaction occured on March, 12th when insider Trent G Kamke sold 2,009 shares worth more than $164,979.08. Insiders at LeMaitre Vascular own 10.8% of the company. Learn More about insider trades at LeMaitre Vascular.

Information on this page was last updated on 3/12/2025.

Bridget A. Ross Insider Trading History at LeMaitre Vascular

See Full Table

Bridget A. Ross Buying and Selling Activity at LeMaitre Vascular

This chart shows Bridget A Ross's buying and selling at LeMaitre Vascular by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

LeMaitre Vascular Company Overview

LeMaitre Vascular logo
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Read More

Today's Range

Now: $91.76
Low: $89.50
High: $92.41

50 Day Range

MA: $87.22
Low: $77.89
High: $104.00

2 Week Range

Now: $91.76
Low: $62.50
High: $109.58

Volume

137,229 shs

Average Volume

161,109 shs

Market Capitalization

$2.07 billion

P/E Ratio

50.14

Dividend Yield

0.94%

Beta

0.89